Australia is carefully awaiting the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://lawsonsiwp618375.wikijournalist.com/576207/retatrutide_australia_a_promising_hope_for_weight_management